Search
Lobeglitazone
go.drugbank.com/drugs/DB09198InvestigationalLobeglitazone is an antidiabetic medication from the thiazolidinedione class of drugs. It primarily functions as an insulin sensitizer by binding and activating Peroxisome Proliferator-Activated Receptors (PPAR) gamma within fat cells. B...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsCiglitazone
go.drugbank.com/drugs/DB09201ExperimentalDeveloped by Takeda Pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class. Ciglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones....
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsTolfenamic acid
go.drugbank.com/drugs/DB09216ApprovedTolfenamic acid, with the formula N-(2-methyl-3-chlorphenyl)-anthranilic acid, is a nonsteroidal anti-inflammatory agent. It was discovered by scientists at Medica Pharmaceutical Company in Finland. It is used in the UK as a treatment fo...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesBlonanserin
go.drugbank.com/drugs/DB09223InvestigationalBlonanserin is an atypical antipsychotic approved in Japan in January, 2008. It offers improved tolerability as it lacks side effects such as extrapyramidal symptoms, excessive sedation, or hypotension. As a second-generation (atypical) ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesMelperone
go.drugbank.com/drugs/DB09224InvestigationalMelperone is an atypical antipsychotic of the butyrophenone chemical class, making it structurally related to the typical antipsychotic haloperidol. Melperone has been used for a span of greater than 30 years in the European Union . It h...
Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme InhibitorsCilnidipine
go.drugbank.com/drugs/DB09232InvestigationalCilnidipine is a dihydropyridine calcium antagonist. It was jointly developed by Fuji Viscera Pharmaceutical Company, Japan and Ajinomoto, Japan and approved in 1995. Compared with other calcium antagonists, cilnidipine can act on the N-...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesEfonidipine
go.drugbank.com/drugs/DB09235InvestigationalEfonidipine is a calcium channel blocker of the dihydropyridine class, commercialized by Shionogi & Co. (Japan). Initially, it was marketed in 1995 under the trade name, Landel. The drug has been shown to block T-type in addition to ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsDoxofylline
go.drugbank.com/drugs/DB09273InvestigationalDoxofylline is a methylxanthine derivative with the presence of a dioxolane group in position 7. As a drug used in the treatment of asthma, doxofylline has shown similar efficacy to theophylline but with significantly fewer side effects ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesArtesunate
go.drugbank.com/drugs/DB09274ApprovedInvestigationalArtesunate is indicated for the initial treatment of severe malaria. The World Health Organization recommends artesunate as first line treatment for severe malaria. Artesunate was developed out of a need for a more hydrophilic derivative...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesPropacetamol
go.drugbank.com/drugs/DB09288InvestigationalPropacetamol is a non-opioid analgesic devoid of the major contraindications. It is a derivative of acetaminophen, or paracetamol, with the molecular formula glycine, N, N-diethyl-,4-(acetylamino)phenyl ester. Propacetamol is a parentera...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers